Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareDxCDNA +0.07%65 Equity-to-Asset is 0.80 as of Jun. 2026, which is 8% above its 10-year median of 0.74. GuruFocus rates CDNA with a GF Score™ of 65/100 and a GF Value™ of $25.20 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, CareDx ranks better than 80.48% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CareDx's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $425.6 Mil. CareDx's Total Assets for the quarter that ended in Jun. 2026 was $533.0 Mil.
Therefore, CareDx's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.80.
The historical rank and industry rank for CareDx's Equity-to-Asset or its related term are showing as below:
CDNA'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.07 Med: 0.74 Max: 0.87
Current: 0.8
During the past 13 years, the highest Equity to Asset Ratio of CareDx was 0.87. The lowest was -0.07. And the median was 0.74.
CDNA's Equity-to-Asset is ranked better than 80.48% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs CDNA: 0.80
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CareDx Equity-to-Asset Related Terms
CareDx Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for CareDx's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CDNA vs NEO, WGS, PSNL: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, CareDx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareDx Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CareDx's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CareDx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareDx (CDNA) has a Equity-to-Asset of 0.80 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CareDx and its competitors. This is near median its historical median of 0.74. According to the industry distribution chart, CareDx ranks #41 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 19.5%.
Is CareDx's Equity-to-Asset too high?
CareDx's current Equity-to-Asset of 0.80 is near median its 10-year median of 0.74. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. CareDx's value of 0.80 is 34.5% above this industry median. Based on the distribution chart, CareDx ranks #41 out of 210 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, CareDx has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Equity-to-Asset compare to NEO and WGS?
According to the Medical Diagnostics & Research industry distribution chart, CareDx ranks #41 out of 210 companies for Equity-to-Asset. This places CareDx in the top 20% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.60. CareDx's value of 0.80 is 34.5% above this benchmark. While the company's 10-year median is 0.74 vs. the industry median of 0.60, CareDx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareDx's current Equity-to-Asset of 0.80 is 34.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CareDx and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareDx's current Equity-to-Asset is 0.80, which is near median its own 10-year median of 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (CDNA) is currently considered Significantly Overvalued. The stock's GF Value™ is $25.20, compared to a current price of $47.03 — trading 86.6% above its estimated fair value. The current Equity-to-Asset is 0.80, which is near median its 10-year median of 0.74 and 34.5% above the Medical Diagnostics & Research industry median of 0.60. CareDx's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CareDx (CDNA), the current Equity-to-Asset is 0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareDx (CDNA) Overvalued in 2026?
Based on GuruFocus' analysis, CareDx stock appears to be overvalued.
The current stock price of $47.03 is trading 86.6% above its estimated GF Value™ of $25.20.
GuruFocus considers CareDx to be Significantly Overvalued.
Key valuation signals for CDNA:
Equity-to-Asset: 0.80 (near median its 10-year median of 0.74)
GF Value™: $25.20 vs. price of $47.03 (86.6% above fair value)
Industry Position: 34.5% above the Medical Diagnostics & Research median (#41 of 210)
No single metric tells the full story. See the CDNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
65GF Score
Get the complete analysis for CDNA
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDNA has been successfully added to your 
